PMID- 23430482
OWN - NLM
STAT- MEDLINE
DCOM- 20140212
LR  - 20240322
IS  - 1559-1182 (Electronic)
IS  - 0893-7648 (Print)
IS  - 0893-7648 (Linking)
VI  - 48
IP  - 1
DP  - 2013 Aug
TI  - Synergy of homocysteine, microRNA, and epigenetics: a novel therapeutic approach 
      for stroke.
PG  - 157-68
LID - 10.1007/s12035-013-8421-y [doi]
AB  - Homocysteine (Hcy) is a thiol-containing amino acid formed during methionine 
      metabolism. Elevated level of Hcy is known as hyperhomocysteinemia (HHcy). HHcy 
      is an independent risk factor for cerebrovascular diseases such as stroke, 
      dementia, Alzheimer's disease, etc. Stroke, which is caused by interruption of 
      blood supply to the brain, is one of the leading causes of death and disability 
      in a number of people worldwide. The HHcy causes an increased carotid artery 
      plaque that may lead to ischemic stroke but the mechanism is currently not well 
      understood. Though mutations or polymorphisms in the key genes of Hcy metabolism 
      pathway have been well elucidated in stroke, emerging evidences suggested 
      epigenetic mechanisms equally play an important role in stroke development such 
      as DNA methylation, chromatin remodeling, RNA editing, noncoding RNAs (ncRNAs), 
      and microRNAs (miRNAs). However, there is no review available yet that describes 
      the role of genetics and epigenetics during HHcy in stroke. The current review 
      highlights the role of genetics and epigenetics in stroke during HHcy and the 
      role of epigenetics in its therapeutics. The review also highlights possible 
      epigenetic mechanisms, potential therapeutic molecules, putative challenges, and 
      approaches to deal with stroke during HHcy.
FAU - Kalani, Anuradha
AU  - Kalani A
AD  - Department of Physiology and Biophysics, School of Medicine, University of 
      Louisville, Louisville, KY 40202, USA.
FAU - Kamat, Pradeep K
AU  - Kamat PK
FAU - Tyagi, Suresh C
AU  - Tyagi SC
FAU - Tyagi, Neetu
AU  - Tyagi N
LA  - eng
GR  - R01 HL107640/HL/NHLBI NIH HHS/United States
GR  - R01 NS051568/NS/NINDS NIH HHS/United States
GR  - HL-107640/HL/NHLBI NIH HHS/United States
GR  - NS-51568/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20130222
PL  - United States
TA  - Mol Neurobiol
JT  - Molecular neurobiology
JID - 8900963
RN  - 0 (MicroRNAs)
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Animals
MH  - *Epigenesis, Genetic
MH  - Homocysteine/*metabolism
MH  - Humans
MH  - Hyperhomocysteinemia/complications
MH  - MicroRNAs/*genetics/metabolism
MH  - RNA Editing/genetics
MH  - Stroke/complications/*genetics/*therapy
PMC - PMC3695063
MID - NIHMS448501
EDAT- 2013/02/23 06:00
MHDA- 2014/02/13 06:00
PMCR- 2014/08/01
CRDT- 2013/02/23 06:00
PHST- 2012/12/14 00:00 [received]
PHST- 2013/01/30 00:00 [accepted]
PHST- 2013/02/23 06:00 [entrez]
PHST- 2013/02/23 06:00 [pubmed]
PHST- 2014/02/13 06:00 [medline]
PHST- 2014/08/01 00:00 [pmc-release]
AID - 10.1007/s12035-013-8421-y [doi]
PST - ppublish
SO  - Mol Neurobiol. 2013 Aug;48(1):157-68. doi: 10.1007/s12035-013-8421-y. Epub 2013 
      Feb 22.